Becton Dickinson and Co (BDX) Stake Raised by OppenheimerFunds Inc.
OppenheimerFunds Inc. lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 550.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,219 shares of the medical instruments supplier’s stock after purchasing an additional 54,351 shares during the period. OppenheimerFunds Inc.’s holdings in Becton Dickinson and were worth $13,917,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in BDX. Colonial Trust Advisors raised its position in Becton Dickinson and by 7.3% during the fourth quarter. Colonial Trust Advisors now owns 3,440 shares of the medical instruments supplier’s stock valued at $736,000 after buying an additional 235 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in Becton Dickinson and by 4.2% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 5,982 shares of the medical instruments supplier’s stock valued at $1,296,000 after buying an additional 242 shares during the period. Greenleaf Trust raised its position in Becton Dickinson and by 18.8% during the first quarter. Greenleaf Trust now owns 1,566 shares of the medical instruments supplier’s stock valued at $339,000 after buying an additional 248 shares during the period. Montag A & Associates Inc. raised its position in Becton Dickinson and by 3.1% during the first quarter. Montag A & Associates Inc. now owns 8,233 shares of the medical instruments supplier’s stock valued at $1,784,000 after buying an additional 249 shares during the period. Finally, Covington Capital Management raised its position in Becton Dickinson and by 1.6% during the fourth quarter. Covington Capital Management now owns 16,214 shares of the medical instruments supplier’s stock valued at $3,471,000 after buying an additional 255 shares during the period. 84.26% of the stock is currently owned by institutional investors.
Several research firms recently weighed in on BDX. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. BMO Capital Markets began coverage on Becton Dickinson and in a research report on Monday, March 5th. They set a “market perform” rating and a $249.00 price target on the stock. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, Citigroup raised Becton Dickinson and from a “neutral” rating to a “buy” rating and upped their price target for the company from $237.00 to $251.00 in a research report on Tuesday, April 10th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $241.19.
Shares of NYSE BDX opened at $233.64 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.12 and a debt-to-equity ratio of 1.07. Becton Dickinson and Co has a one year low of $190.06 and a one year high of $248.39. The stock has a market capitalization of $62.14 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 1.62 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.63 by $0.02. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The firm had revenue of $4.22 billion for the quarter, compared to the consensus estimate of $4.12 billion. During the same quarter in the previous year, the company posted $2.30 earnings per share. The business’s quarterly revenue was up 42.2% compared to the same quarter last year. equities research analysts anticipate that Becton Dickinson and Co will post 10.99 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 8th will be paid a $0.75 dividend. The ex-dividend date of this dividend is Thursday, June 7th. This represents a $3.00 dividend on an annualized basis and a yield of 1.28%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 31.65%.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.